This report was recently updated on April 28 2024 with the latest and most recent
market numbers
Global Non-oncology Biologics and Biosimilars Market Size, Trends & Analysis - Forecasts to 2028 By Drug Category (Monoclonal Antibody, Enzyme Replacement Therapy, Toxins, Fusion Proteins, Vaccines, Insulin, Hormones, Gene Therapy, Cell Therapy, and Others), By Application Type (Cardiology, Dermatology, Hematology, Endocrinology, Neurology, Immunology, Respiratory, Rheumatology, Ophthalmology, and Others), By Product Type (Biologics and Biosimilars), and By Region (North America, Asia Pacific, Central and South America, Europe, and Middle East and Africa), Competitive Landscape, Company Market Share Analysis, and End User Analysis
The global non-oncology biologics and biosimilars market is expected to exhibit a CAGR of 22.6% from 2023 to 2028. Non-oncology biologics and biosimilars are crucial categories in medicine, specifically in biopharmaceuticals. Non-oncology biologics are products derived from living organisms or contain components of living organisms used for treating diseases other than cancer. They include therapeutic proteins, vaccines, and other biological products for autoimmune, infectious, and inflammatory disorders. Biosimilars are biologic medicinal treatments remarkably similar to a previously authorized biological product known as the original product. They are intended to make healthcare more inexpensive and accessible to patients. Non-oncology biologics and biosimilars significantly impact modern healthcare by providing effective treatment options for various diseases and conditions. In contrast, biosimilars contribute to increasing access to critical therapies by offering more cost-effective alternatives.
Many factors drive the global non-oncology biologics and biosimilars market growth. The increasing incidence of chronic diseases such as autoimmune diseases, Type 2 diabetes, and other non-oncology problems has produced a growing need for effective biologic therapies, propelling the non-oncology biologics and biosimilars market forward. Advances in biotechnology and biopharmaceutical manufacturing processes have enabled the development and production of complex non-oncology biologics and biosimilars more efficiently, leading to increased availability and accessibility of these treatments. The high cost of many non-oncology biologics has led to an increasing demand for more affordable alternatives, such as biosimilars. Biosimilars provide a cost-effective choice for individuals and healthcare systems, increasing their acceptance while contributing to the global market's development.
Despite the promising growth prospects, the global non-oncology biologics and biosimilars market faces certain restraints that hinder its growth. The regulatory approval process for non-oncology biologics and biosimilars can be rigorous and time-consuming, requiring extensive clinical data to demonstrate similarity and efficacy. The production of non-oncology biologics and biosimilars involves complex manufacturing processes, which can be challenging to replicate precisely, leading to potential product quality and consistency variations. Maintaining consistent quality can be a restraint for manufacturers in this market.
Based on the drug category, the market is segmented into monoclonal antibody, enzyme replacement therapy, toxins, fusion proteins, vaccines, insulin, hormones, gene therapy, cell therapy, and others. The monoclonal antibody segment is expected to be the largest segment during the forecast period. Monoclonal antibodies offer targeted therapy, precise binding to specific antigens, and reduced side effects, making them favourable for conditions like autoimmune disorders and inflammatory diseases. Their ability to modulate immune responses and high specificity contribute to their widespread adoption and market dominance.
The hormones segment is expected to be the fastest-growing segment in the global non-oncology biologics and biosimilars market during the forecast period. This is owing to the rising incidence of endocrine illnesses and hormonal imbalances, exacerbated by lifestyle shifts and an aging population. Increasing awareness about hormone replacement therapies and the expanding applications of biologics in treating conditions like diabetes and growth hormone deficiencies further contribute to the segment's rapid growth.
Based on product type, the market is segmented into biologics and biosimilars. The biologics segment is expected to be the largest segment during the forecast period. Biologics provide specific and powerful therapies for various illnesses, taking advantage of their capacity to target specific disease pathways and give individualized therapeutic methods. This has resulted in widespread acceptance, leading to the segment's market dominance.
The biosimilars segment is expected to be the fastest-growing segment in the global non-oncology biologics and biosimilars market. With the patent expirations of several biologic drugs, the market has opened up for biosimilar manufacturers, improving accessibility and competition. Additionally, the growing emphasis on healthcare cost containment and favorable regulatory support further accelerates the adoption and growth of biosimilars.
On the basis of application type, the market is segmented into cardiology, dermatology, hematology, endocrinology, neurology, immunology, respiratory, rheumatology, ophthalmology, and others. The cardiology segment is expected to be the largest segment during the forecast period, owing to the rising incidence of cardiovascular disorders, such as heart failure, high blood pressure, and coronary artery disease, globally. The growing elderly population, physical inactivity, and poor dietary habits all contribute to the increasing prevalence of these illnesses, fueling demand for effective biologic therapies and cost-efficient biosimilars in the cardiology sector.
The neurology segment is expected to be the fastest-growing segment in the global non-oncology biologics and biosimilars market during the forecast period due to the increasing number of patients with neurological disorders, such as multiple sclerosis, Alzheimer's disease, and Parkinson's disease. Additionally, the growing understanding of the complex mechanisms underlying these conditions has facilitated the development of innovative biologic therapies and biosimilars, addressing the unmet medical needs in this field and driving rapid growth in this segment.
North America is analysed to account for the largest share in the global non-oncology biologics and biosimilars market during the forecast period. The region offers a comprehensive regulatory environment for biosimilar approval and is witnessing a significant prevalence in chronic conditions. Additionally, a large aging population and favorable reimbursement policies drive demand for non-oncology biologics and biosimilars. Market leaders like the United States and Canada offer a competitive landscape, encouraging research and development, making North America a significant contributor to the global market.
Asia Pacific is expected to be the fastest-growing region across the global non-oncology biologics and biosimilars market. This region has a huge patient population, a rising incidence of long-term illnesses, robust medical infrastructure, and an increasing demand for low-cost treatment choices. Additionally, supportive government initiatives, growing investments in healthcare, and the presence of key market players contribute to the rapid expansion of the APAC market.
Key players operating in the global non-oncology biologics and biosimilars market include AbbVie Inc., Sanofi, Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche, Johnson & Johnson, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Takeda Pharmaceuticals, BioMarin Pharmaceuticals, GSK, AstraZeneca, and Biogen, among others.
Please note: This is not an exhaustive list of companies profiled in the report.
In July 2023, Biocon Biologics Ltd launched the HULIO injection, a biosimilar to Humira, available to patients in the U.S. after five years in Europe and two years in Canada. Moreover, acquiring Viatris' global biosimilar business aims to provide more accessible treatment options.
In May 2020, GlaxoSmithKline and Samsung Biologics partnered to expand their biopharmaceutical manufacturing capacity, providing flexible, large-scale manufacturing capacity to supplement GSK's existing manufacturing network and meet future needs for innovative therapies.
1 STRATEGIC INSIGHTS ON NEW REVENUE POCKETS
1.1 Strategic Opportunity & Attractiveness Analysis
1.1.1 Hot Revenue Pockets
1.1.2 Market Attractiveness Score
1.1.3 Revenue Impacting Opportunity
1.1.4 High Growing Region/Country
1.1.5 Competitor Analysis
1.1.6 Consumer Analysis
1.2 Global Market Estimates' View
1.3 Strategic Insights across Business Functions
1.3.1 For Chief Executive Officers
1.3.2 For Chief Marketing Officers
1.3.3 For Chief Strategy Officers
1.4 Evaluate the Potential of your Existing Business Lines vs. New Lines to Enter Into
2 TECHNOLOGICAL TRENDS
2.1 Technological Adoption Rate
2.2 Current Trend Impact Analysis
2.3 Future Trend Impact Analysis
3.1 Market Pyramid Analysis
3.1.1 Introduction
3.1.2 Adjacent Market Opportunities
3.1.3 Ancillary Market Opportunities
3.2 Demand Side Analysis
3.2.1 Market Drivers: Impact Analysis
3.2.2 Market Restraints: Impact Analysis
3.2.3 Market Opportunities: Impact Analysis
3.2.4 Market Challenges: Impact Analysis
3.3 Supply Side Analysis
3.3.1 Porter’s Five Forces Analysis
3.3.1.1 Threat of New Entrants
3.3.1.2 Threat of New Substitutes
3.3.1.3 Bargaining Power of Suppliers
3.3.1.4 Bargaining Power of Buyers
3.3.1.5 Intensity of Competitive Rivalry
3.3.2 SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)
3.3.2.1 Political Landscape
3.3.2.2 Economic Landscape
3.3.2.3 Social Landscape
3.3.2.4 Technology Landscape
3.3.3 Value Chain Analysis
3.3.4 Trend Analysis
3.3.5 Gap Analysis
3.3.6 Cost Analysis
4 GLOBAL NON-ONCOLOGY BIOLOGICS AND BIOSIMILARSLARS MARKET, BY DRUG CATEGORY
4.1 Introduction
4.2 Non-oncology Biologics and Biosimilarslars Market: Drug Category Scope Key Takeaways
4.3 Revenue Growth Analysis, 2022 & 2028
4.4 Monoclonal Antibody
4.4.1 Monoclonal Antibody Market Estimates and Forecast, 2020-2028 (USD Billion)
4.5 Enzyme Replacement Therapy
4.5.1 Enzyme Replacement Therapy Market Estimates and Forecast, 2020-2028 (USD Billion)
4.6 Toxins
4.6.1 Toxins Market Estimates and Forecast, 2020-2028 (USD Billion)
4.7 Cell Therapy
4.7.1 Cell Therapy Market Estimates and Forecast, 2020-2028 (USD Billion)
4.8 Gene Therapy
4.8.1 Gene Therapy Market Estimates and Forecast, 2020-2028 (USD Billion)
4.9 Hormones
4.9.1 Hormones Market Estimates and Forecast, 2020-2028 (USD Billion)
4.10 Insulin
4.10.1 Insulin Market Estimates and Forecast, 2020-2028 (USD Billion)
4.11 Vaccines
4.11.1 Vaccines Market Estimates and Forecast, 2020-2028 (USD Billion)
4.12 Fusion Proteins
4.12.1 Fusion Proteins Market Estimates and Forecast, 2020-2028 (USD Billion)
4.13 Other Categories
4.13.1 Other Categories Market Estimates and Forecast, 2020-2028 (USD Billion)
5 GLOBAL NON-ONCOLOGY BIOLOGICS AND BIOSIMILARSLARS MARKET, BY PRODUCT TYPE
5.1 Introduction
5.2 Non-oncology Biologics and Biosimilarslars Market: Product Type Scope Key Takeaways
5.3 Revenue Growth Analysis, 2022 & 2028
5.4 Biologics
5.4.1 Biologics Market Estimates and Forecast, 2020-2028 (USD Billion)
5.5 Biosimilars
5.5.1 Biosimilars Market Estimates and Forecast, 2020-2028 (USD Billion)
6 GLOBAL NON-ONCOLOGY BIOLOGICS AND BIOSIMILARSLARS MARKET, BY APPLICATION TYPE
6.1 Introduction
6.2 Non-oncology Biologics and Biosimilarslars Market: Application Type Scope Key Takeaways
6.3 Revenue Growth Analysis, 2022 & 2028
6.4 Cardiology
6.4.1 Cardiology Market Estimates and Forecast, 2020-2028 (USD Billion)
6.5 Dermatology
6.5.1 Dermatology Market Estimates and Forecast, 2020-2028 (USD Billion)
6.6 Hematology
6.6.1 Hematology Market Estimates and Forecast, 2020-2028 (USD Billion)
6.7 Endocrinology
6.7.1 Endocrinology Market Estimates and Forecast, 2020-2028 (USD Billion)
6.8 Neurology
6.8.1 Neurology Market Estimates and Forecast, 2020-2028 (USD Billion)
6.9 Immunology
6.9.1 Immunology Market Estimates and Forecast, 2020-2028 (USD Billion)
6.10 Respiratory
6.10.1 Respiratory Market Estimates and Forecast, 2020-2028 (USD Billion)
6.11 Rheumatology
6.11.1 Rheumatology Market Estimates and Forecast, 2020-2028 (USD Billion)
6.12 Ophthalmology
6.12.1 Ophthalmology Market Estimates and Forecast, 2020-2028 (USD Billion)
6.13 Other Applications
6.13.1 Other Applications Market Estimates and Forecast, 2020-2028 (USD Billion)
7 GLOBAL NON-ONCOLOGY BIOLOGICS AND BIOSIMILARSLARS MARKET, BY REGION
7.1 Introduction
7.2 North America Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.2.1 By Drug Category
7.2.2 By Product Type
7.2.3 By Application Type
7.2.4 By Country
7.2.4.1 U.S. Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.2.4.1.1 By Drug Category
7.2.4.1.2 By Product Type
7.2.4.1.3 By Application Type
7.2.4.2 Canada Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.2.4.2.1 By Drug Category
7.2.4.2.2 By Product Type
7.2.4.2.3 By Application Type
7.2.4.3 Mexico Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.2.4.3.1 By Drug Category
7.2.4.3.2 By Product Type
7.2.4.3.3 By Application Type
7.3 Europe Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.3.1 By Drug Category
7.3.2 By Product Type
7.3.3 By Application Type
7.3.4 By Country
7.3.4.1 Germany Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.3.4.1.1 By Drug Category
7.3.4.1.2 By Product Type
7.3.4.1.3 By Application Type
7.3.4.2 U.K. Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.3.4.2.1 By Drug Category
7.3.4.2.2 By Product Type
7.3.4.2.3 By Application Type
7.3.4.3 France Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.3.4.3.1 By Drug Category
7.3.4.3.2 By Product Type
7.3.4.3.3 By Application Type
7.3.4.4 Italy Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.3.4.4.1 By Drug Category
7.3.4.4.2 By Product Type
7.2.4.4.3 By Application Type
7.3.4.5 Spain Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.3.4.5.1 By Drug Category
7.3.4.5.2 By Product Type
7.2.4.5.3 By Application Type
7.3.4.6 Netherlands Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.3.4.7.1 By Drug Category
7.3.4.7.2 By Product Type
7.2.4.7.3 By Application Type
7.3.4.7 Rest of Europe Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.3.4.7.1 By Drug Category
7.3.4.7.2 By Product Type
7.2.4.7.3 By Application Type
7.4 Asia Pacific Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.4.1 By Drug Category
7.4.2 By Product Type
7.4.3 By Application Type
7.4.4 By Country
7.4.4.1 China Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.4.4.1.1 By Drug Category
7.4.4.1.2 By Product Type
7.4.4.1.3 By Application Type
7.4.4.2 Japan Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.4.4.2.1 By Drug Category
7.4.4.2.2 By Product Type
7.4.4.2.3 By Application Type
7.4.4.3 India Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.4.4.3.1 By Drug Category
7.4.4.3.2 By Product Type
7.4.4.3.3 By Application Type
7.4.4.4 South Korea Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.4.4.4.1 By Drug Category
7.4.4.4.2 By Product Type
7.4.4.4.3 By Application Type
7.4.4.5 Singapore Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.4.4.5.1 By Drug Category
7.4.4.5.2 By Product Type
7.4.4.5.3 By Application Type
7.4.4.6 Malaysia Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.4.4.7.1 By Drug Category
7.4.4.7.2 By Product Type
7.4.4.7.3 By Application Type
7.4.4.7 Thailand Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.4.4.7.1 By Drug Category
7.4.4.7.2 By Product Type
7.4.4.7.3 By Application Type
7.4.4.8 Indonesia Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.4.4.8.1 By Drug Category
7.4.4.8.2 By Product Type
7.4.4.8.3 By Application Type
7.4.4.9 Vietnam Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.4.4.9.1 By Drug Category
7.4.4.9.2 By Product Type
7.4.4.9.3 By Application Type
7.4.4.10 Taiwan Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.4.4.10.1 By Drug Category
7.4.4.10.2 By Product Type
7.4.4.10.3 By Application Type
7.4.4.11 Rest of Asia Pacific Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.4.4.11.1 By Drug Category
7.4.4.11.2 By Product Type
7.4.4.11.3 By Application Type
7.5 Middle East and Africa Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.5.1 By Drug Category
7.5.2 By Product Type
7.5.3 By Application Type
7.5.4 By Country
7.5.4.1 Saudi Arabia Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.5.4.1.1 By Drug Category
7.5.4.1.2 By Product Type
7.5.4.1.3 By Application Type
7.5.4.2 U.A.E. Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.5.4.2.1 By Drug Category
7.5.4.2.2 By Product Type
7.5.4.2.3 By Application Type
7.5.4.3 Israel Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.5.4.3.1 By Drug Category
7.5.4.3.2 By Product Type
7.5.4.3.3 By Application Type
7.5.4.4 South Africa Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.5.4.4.1 By Drug Category
7.5.4.4.2 By Product Type
7.5.4.4.3 By Application Type
7.5.4.5 Rest of Middle East and Africa Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.5.4.5.1 By Drug Category
7.5.4.5.2 By Product Type
7.5.4.5.2 By Application Type
7.6 Central and South America Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.7.1 By Drug Category
7.7.2 By Product Type
7.7.3 By Application Type
7.7.4 By Country
7.7.4.1 Brazil Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.7.4.1.1 By Drug Category
7.7.4.1.2 By Product Type
7.7.4.1.3 By Application Type
7.7.4.2 Argentina Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.7.4.2.1 By Drug Category
7.7.4.2.2 By Product Type
7.7.4.2.3 By Application Type
7.7.4.3 Chile Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.7.4.3.1 By Drug Category
7.7.4.3.2 By Product Type
7.7.4.3.3 By Application Type
7.7.4.4 Rest of Central and South America Non-oncology Biologics and Biosimilarslars Market Estimates and Forecast, 2020-2028 (USD Billion)
7.7.4.4.1 By Drug Category
7.7.4.4.2 By Product Type
7.7.4.4.3 By Application Type
8 COMPETITIVE LANDCAPE
8.1 Company Market Share Analysis
8.2 Four Quadrant Positioning Matrix
8.2.1 Market Leaders
8.2.2 Market Visionaries
8.2.3 Market Challengers
8.2.4 Niche Market Players
8.3 Vendor Landscape
8.3.1 North America
8.3.2 Europe
8.3.3 Asia Pacific
8.3.4 Rest of the World
8.4 Company Profiles
8.4.1 AbbVie Inc.
8.4.1.1 Business Description & Financial Analysis
8.4.1.2 SWOT Analysis
8.4.1.3 Products & Services Offered
8.4.1.4 Strategic Alliances between Business Partners
8.4.2 Sanofi
8.4.2.1 Business Description & Financial Analysis
8.4.2.2 SWOT Analysis
8.4.2.3 Products & Services Offered
8.4.2.4 Strategic Alliances between Business Partners
8.4.3 Amgen Inc.
8.4.3.1 Business Description & Financial Analysis
8.4.3.2 SWOT Analysis
8.4.3.3 Products & Services Offered
8.4.3.4 Strategic Alliances between Business Partners
8.4.4 Bristol-Myers Squibb Company
8.4.4.1 Business Description & Financial Analysis
8.4.4.2 SWOT Analysis
8.4.4.3 Products & Services Offered
8.4.4.4 Strategic Alliances between Business Partners
8.4.5 Eli Lilly and Company
8.4.5.1 Business Description & Financial Analysis
8.4.5.2 SWOT Analysis
8.4.5.3 Products & Services Offered
8.4.5.4 Strategic Alliances between Business Partners
8.4.6 F. Hoffmann-La Roche Ltd.
8.4.7.1 Business Description & Financial Analysis
8.4.7.2 SWOT Analysis
8.4.7.3 Products & Services Offered
8.4.7.4 Strategic Alliances between Business Partners
8.4.7 Johnson & Johnson
8.4.7.1 Business Description & Financial Analysis
8.4.7.2 SWOT Analysis
8.4.7.3 Products & Services Offered
8.4.8.4 Strategic Alliances between Business Partners
8.4.8 Novartis AG
8.4.8.1 Business Description & Financial Analysis
8.4.8.2 SWOT Analysis
8.4.8.3 Products & Services Offered
8.4.8.4 Strategic Alliances between Business Partners
8.4.9 Pfizer Inc.
8.4.9.1 Business Description & Financial Analysis
8.4.9.2 SWOT Analysis
8.4.9.3 Products & Services Offered
8.4.9.4 Strategic Alliances between Business Partners
8.4.10 Other Companies
8.4.10.1 Business Description & Financial Analysis
8.4.10.2 SWOT Analysis
8.4.10.3 Products & Services Offered
8.4.10.4 Strategic Alliances between Business Partners
9 RESEARCH METHODOLOGY
9.1 Market Introduction
9.1.1 Market Definition
9.1.2 Market Scope & Segmentation
9.2 Information Procurement
9.2.1 Secondary Research
9.2.1.1 Purchased Databases
9.2.1.2 GMEs Internal Data Repository
9.2.1.3 Secondary Resources & Third Party Perspectives
9.2.1.4 Company Information Sources
9.2.2 Primary Research
9.2.2.1 Various Types of Respondents for Primary Interviews
9.2.2.2 Number of Interviews Conducted throughout the Research Process
9.2.2.3 Primary Stakeholders
9.2.2.4 Discussion Guide for Primary Participants
9.2.3 Expert Panels
9.2.3.1 Expert Panels Across 30+ Industry
9.2.4 Paid Local Experts
9.2.4.1 Paid Local Experts Across 30+ Industry Across each Region
9.3 Market Estimation
9.3.1 Top-Down Approach
9.3.1.1 Macro-Economic Indicators Considered
9.3.1.2 Micro-Economic Indicators Considered
9.3.2 Bottom Up Approach
9.3.2.1 Company Share Analysis Approach
9.3.2.2 Estimation of Potential Product Sales
9.4 Data Triangulation
9.4.1 Data Collection
9.4.2 Time Series, Cross Sectional & Panel Data Analysis
9.4.3 Cluster Analysis
9.5 Analysis and Output
9.5.1 Inhouse AI Based Real Time Analytics Tool
9.5.2 Output From Desk & Primary Research
9.6 Research Assumptions & Limitations
9.7.1 Research Assumptions
9.7.2 Research Limitations
LIST OF TABLES
1 Global Non-oncology Biologics and Biosimilarslars Market, By Drug Category, 2020-2028 (USD Billion)
2 Monoclonal Antibody Market, By Region, 2020-2028 (USD Billion)
3 Enzyme Replacement Therapy Market, By Region, 2020-2028 (USD Billion)
4 TOXINS Market, By Region, 2020-2028 (USD Billion)
5 Cell Therapy Market, By Region, 2020-2028 (USD Billion)
6 Gene Therapy Market, By Region, 2020-2028 (USD Billion)
7 Hormones Market, By Region, 2020-2028 (USD Billion)
8 Insulin Market, By Region, 2020-2028 (USD Billion)
9 Vaccines Market, By Region, 2020-2028 (USD Billion)
10 Fusion Proteins Market, By Region, 2020-2028 (USD Billion)
11 Other Categories Market, By Region, 2020-2028 (USD Billion)
12 Global Non-oncology Biologics and Biosimilarslars Market, By Product Type, 2020-2028 (USD Billion)
13 Biologics Market, By Region, 2020-2028 (USD Billion)
14 Biosimilars Market, By Region, 2020-2028 (USD Billion)
15 Global Non-oncology Biologics and Biosimilarslars Market, By Application Type, 2020-2028 (USD Billion)
16 Cardiology Market, By Region, 2020-2028 (USD Billion)
17 Dermatology Market, By Region, 2020-2028 (USD Billion)
18 Hematology Market, By Region, 2020-2028 (USD Billion)
19 Endocrinology Market, By Region, 2020-2028 (USD Billion)
20 Neurology Market, By Region, 2020-2028 (USD Billion)
21 Immunology Market, By Region, 2020-2028 (USD Billion)
22 Respiratory Market, By Region, 2020-2028 (USD Billion)
23 Rheumatology Market, By Region, 2020-2028 (USD Billion)
24 Ophthalmology Market, By Region, 2020-2028 (USD Billion)
25 Other Applications Market, By Region, 2020-2028 (USD Billion)
26 Regional Analysis, 2020-2028 (USD Billion)
27 North America Non-oncology Biologics and Biosimilarslars Market, By Drug Category, 2020-2028 (USD Billion)
28 North America Non-oncology Biologics and Biosimilarslars Market, By Product Type, 2020-2028 (USD Billion)
29 North America Non-oncology Biologics and Biosimilarslars Market, By Application Type, 2020-2028 (USD Billion)
30 North America Non-oncology Biologics and Biosimilarslars Market, By Country, 2020-2028 (USD Billion)
31 U.S. Non-oncology Biologics and Biosimilarslars Market, By Drug Category, 2020-2028 (USD Billion)
32 U.S. Non-oncology Biologics and Biosimilarslars Market, By Product Type, 2020-2028 (USD Billion)
33 U.S. Non-oncology Biologics and Biosimilarslars Market, By Application Type, 2020-2028 (USD Billion)
34 Canada Non-oncology Biologics and Biosimilarslars Market, By Drug Category, 2020-2028 (USD Billion)
35 Canada Non-oncology Biologics and Biosimilarslars Market, By Product Type, 2020-2028 (USD Billion)
36 Canada Non-oncology Biologics and Biosimilarslars Market, By Application Type, 2020-2028 (USD Billion)
37 Mexico Non-oncology Biologics and Biosimilarslars Market, By Drug Category, 2020-2028 (USD Billion)
38 Mexico Non-oncology Biologics and Biosimilarslars Market, By Product Type, 2020-2028 (USD Billion)
39 Mexico Non-oncology Biologics and Biosimilarslars Market, By Application Type, 2020-2028 (USD Billion)
40 Europe Non-oncology Biologics and Biosimilarslars Market, By Drug Category, 2020-2028 (USD Billion)
41 Europe Non-oncology Biologics and Biosimilarslars Market, By Product Type, 2020-2028 (USD Billion)
42 Europe Non-oncology Biologics and Biosimilarslars Market, By Application Type, 2020-2028 (USD Billion)
43 Europe Non-oncology Biologics and Biosimilarslars Market, By COUNTRY, 2020-2028 (USD Billion)
44 Germany Non-oncology Biologics and Biosimilarslars Market, By Drug Category, 2020-2028 (USD Billion)
45 Germany Non-oncology Biologics and Biosimilarslars Market, By Product Type, 2020-2028 (USD Billion)
46 Germany Non-oncology Biologics and Biosimilarslars Market, By Application Type, 2020-2028 (USD Billion)
47 U.K. Non-oncology Biologics and Biosimilarslars Market, By Drug Category, 2020-2028 (USD Billion)
48 U.K. Non-oncology Biologics and Biosimilarslars Market, By Product Type, 2020-2028 (USD Billion)
49 U.K. Non-oncology Biologics and Biosimilarslars Market, By Application Type, 2020-2028 (USD Billion)
50 France Non-oncology Biologics and Biosimilarslars Market, By Drug Category, 2020-2028 (USD Billion)
51 France Non-oncology Biologics and Biosimilarslars Market, By Product Type, 2020-2028 (USD Billion)
52 France Non-oncology Biologics and Biosimilarslars Market, By Application Type, 2020-2028 (USD Billion)
53 Italy Non-oncology Biologics and Biosimilarslars Market, By Drug Category, 2020-2028 (USD Billion)
54 Italy Non-oncology Biologics and Biosimilarslars Market, By Product Type, 2020-2028 (USD Billion)
55 Italy Non-oncology Biologics and Biosimilarslars Market, By Application Type, 2020-2028 (USD Billion)
56 Spain Non-oncology Biologics and Biosimilarslars Market, By Drug Category, 2020-2028 (USD Billion)
57 Spain Non-oncology Biologics and Biosimilarslars Market, By Product Type, 2020-2028 (USD Billion)
58 Spain Non-oncology Biologics and Biosimilarslars Market, By Application Type, 2020-2028 (USD Billion)
59 Rest Of Europe Non-oncology Biologics and Biosimilarslars Market, By Drug Category, 2020-2028 (USD Billion)
60 Rest Of Europe Non-oncology Biologics and Biosimilarslars Market, By Product Type, 2020-2028 (USD Billion)
61 Rest of Europe Non-oncology Biologics and Biosimilarslars Market, By Application Type, 2020-2028 (USD Billion)
62 Asia Pacific Non-oncology Biologics and Biosimilarslars Market, By Drug Category, 2020-2028 (USD Billion)
63 Asia Pacific Non-oncology Biologics and Biosimilarslars Market, By Product Type, 2020-2028 (USD Billion)
64 Asia Pacific Non-oncology Biologics and Biosimilarslars Market, By Application Type, 2020-2028 (USD Billion)
65 Asia Pacific Non-oncology Biologics and Biosimilarslars Market, By Country, 2020-2028 (USD Billion)
66 China Non-oncology Biologics and Biosimilarslars Market, By Drug Category, 2020-2028 (USD Billion)
67 China Non-oncology Biologics and Biosimilarslars Market, By Product Type, 2020-2028 (USD Billion)
68 China Non-oncology Biologics and Biosimilarslars Market, By Application Type, 2020-2028 (USD Billion)
69 India Non-oncology Biologics and Biosimilarslars Market, By Drug Category, 2020-2028 (USD Billion)
70 India Non-oncology Biologics and Biosimilarslars Market, By Product Type, 2020-2028 (USD Billion)
71 India Non-oncology Biologics and Biosimilarslars Market, By Application Type, 2020-2028 (USD Billion)
72 Japan Non-oncology Biologics and Biosimilarslars Market, By Drug Category, 2020-2028 (USD Billion)
73 Japan Non-oncology Biologics and Biosimilarslars Market, By Product Type, 2020-2028 (USD Billion)
74 Japan Non-oncology Biologics and Biosimilarslars Market, By Application Type, 2020-2028 (USD Billion)
75 South Korea Non-oncology Biologics and Biosimilarslars Market, By Drug Category, 2020-2028 (USD Billion)
76 South Korea Non-oncology Biologics and Biosimilarslars Market, By Product Type, 2020-2028 (USD Billion)
77 South Korea Non-oncology Biologics and Biosimilarslars Market, By Application Type, 2020-2028 (USD Billion)
78 Thailand Non-oncology Biologics and Biosimilarslars Market, By Drug Category, 2020-2028 (USD Billion)
79 Thailand Non-oncology Biologics and Biosimilarslars Market, By Product Type, 2020-2028 (USD Billion)
80 Thailand Non-oncology Biologics and Biosimilarslars Market, By Application Type, 2020-2028 (USD Billion)
81 Rest Of Asia pacific Non-oncology Biologics and Biosimilarslars Market, By Drug Category, 2020-2028 (USD Billion)
82 Rest Of Asia Pacific Non-oncology Biologics and Biosimilarslars Market, By Product Type, 2020-2028 (USD Billion)
83 Rest of Asia pacific Non-oncology Biologics and Biosimilarslars Market, By Application Type, 2020-2028 (USD Billion)
84 Middle East and Africa Non-oncology Biologics and Biosimilarslars Market, By Drug Category, 2020-2028 (USD Billion)
85 Middle East and Africa Non-oncology Biologics and Biosimilarslars Market, By Product Type, 2020-2028 (USD Billion)
86 Middle East and Africa Non-oncology Biologics and Biosimilarslars Market, By Application Type, 2020-2028 (USD Billion)
87 Middle East and Africa Non-oncology Biologics and Biosimilarslars Market, By Country, 2020-2028 (USD Billion)
88 Saudi Arabia Non-oncology Biologics and Biosimilarslars Market, By Drug Category, 2020-2028 (USD Billion)
89 Saudi Arabia Non-oncology Biologics and Biosimilarslars Market, By Product Type, 2020-2028 (USD Billion)
90 Saudi Arabia Non-oncology Biologics and Biosimilarslars Market, By Application Type, 2020-2028 (USD Billion)
91 UAE Non-oncology Biologics and Biosimilarslars Market, By Drug Category, 2020-2028 (USD Billion)
92 UAE Non-oncology Biologics and Biosimilarslars Market, By Product Type, 2020-2028 (USD Billion)
93 UAE Non-oncology Biologics and Biosimilarslars Market, By Application Type, 2020-2028 (USD Billion)
94 Rest Of Middle East and Africa Non-oncology Biologics and Biosimilarslars Market, By Drug Category, 2020-2028 (USD Billion)
95 Rest Of Middle East and Africa Non-oncology Biologics and Biosimilarslars Market, By Product Type, 2020-2028 (USD Billion)
96 Rest of Middle East and Africa Non-oncology Biologics and Biosimilarslars Market, By Application Type, 2020-2028 (USD Billion)
97 Central and South America Non-oncology Biologics and Biosimilarslars Market, By Drug Category, 2020-2028 (USD Billion)
98 Central and South America Non-oncology Biologics and Biosimilarslars Market, By Product Type, 2020-2028 (USD Billion)
99 Central and South America Non-oncology Biologics and Biosimilarslars Market, By Application Type, 2020-2028 (USD Billion)
100 Central and South America Non-oncology Biologics and Biosimilarslars Market, By Country, 2020-2028 (USD Billion)
101 Brazil Non-oncology Biologics and Biosimilarslars Market, By Drug Category, 2020-2028 (USD Billion)
102 Brazil Non-oncology Biologics and Biosimilarslars Market, By Application Type, 2020-2028 (USD Billion)
103 Brazil Non-oncology Biologics and Biosimilarslars Market, By Product Type, 2020-2028 (USD Billion)
104 Argentina Non-oncology Biologics and Biosimilarslars Market, By Drug Category, 2020-2028 (USD Billion)
105 Argentina Non-oncology Biologics and Biosimilarslars Market, By Product Type, 2020-2028 (USD Billion)
106 Argentina Non-oncology Biologics and Biosimilarslars Market, By Application Type, 2020-2028 (USD Billion)
107 Chile Non-oncology Biologics and Biosimilarslars Market, By Drug Category, 2020-2028 (USD Billion)
108 Chile Non-oncology Biologics and Biosimilarslars Market, By Product Type, 2020-2028 (USD Billion)
109 Chile Non-oncology Biologics and Biosimilarslars Market, By Application Type, 2020-2028 (USD Billion)
110 Rest Of Central and South America Non-oncology Biologics and Biosimilarslars Market, By Drug Category, 2020-2028 (USD Billion)
111 Rest Of Central and South America Non-oncology Biologics and Biosimilarslars Market, By Product Type, 2020-2028 (USD Billion)
112 Rest of Central and South America Non-oncology Biologics and Biosimilarslars Market, By Application Type, 2020-2028 (USD Billion)
113 AbbVie Inc.: Products & Services Offering
114 Sanofi: Products & Services Offering
115 Amgen Inc.: Products & Services Offering
116 Bristol-Myers Squibb Company: Products & Services Offering
117 Eli Lilly and Company: Products & Services Offering
118 F. Hoffmann-La Roche Ltd.: Products & Services Offering
119 Johnson & Johnson : Products & Services Offering
120 Novartis AG: Products & Services Offering
121 Pfizer Inc., Inc: Products & Services Offering
122 Other Companies: Products & Services Offering
LIST OF FIGURES
1 Global Non-oncology Biologics and Biosimilarslars Market Overview
2 Global Non-oncology Biologics and Biosimilarslars Market Value From 2020-2028 (USD Billion)
3 Global Non-oncology Biologics and Biosimilarslars Market Share, By Drug Category (2022)
4 Global Non-oncology Biologics and Biosimilarslars Market Share, By Product Type (2022)
5 Global Non-oncology Biologics and Biosimilarslars Market Share, By Application Type (2022)
6 Global Non-oncology Biologics and Biosimilarslars Market, By Region (Asia Pacific Market)
7 Technological Trends In Global Non-oncology Biologics and Biosimilarslars Market
8 Four Quadrant Competitor Positioning Matrix
9 Impact Of Macro & Micro Indicators On The Market
10 Impact Of Key Drivers On The Global Non-oncology Biologics and Biosimilarslars Market
11 Impact Of Challenges On The Global Non-oncology Biologics and Biosimilarslars Market
12 Porter’s Five Forces Analysis
13 Global Non-oncology Biologics and Biosimilarslars Market: By Drug Category Scope Key Takeaways
14 Global Non-oncology Biologics and Biosimilarslars Market, By Drug Category Segment: Revenue Growth Analysis
15 Monoclonal Antibody Market, By Region, 2020-2028 (USD Billion)
16 Enzyme Replacement Therapy Market, By Region, 2020-2028 (USD Billion)
17 Toxins Market, By Region, 2020-2028 (USD Billion)
18 Cell Therapy Market, By Region, 2020-2028 (USD Billion)
19 Gene Therapy Market, By Region, 2020-2028 (USD Billion)
20 Hormones Market, By Region, 2020-2028 (USD Billion)
21 Insulin Market, By Region, 2020-2028 (USD Billion)
22 Vaccines Market, By Region, 2020-2028 (USD Billion)
23 Fusion Proteins Market, By Region, 2020-2028 (USD Billion)
24 Other Categories Market, By Region, 2020-2028 (USD Billion)
25 Global Non-oncology Biologics and Biosimilarslars Market: By Product Type Scope Key Takeaways
26 Global Non-oncology Biologics and Biosimilarslars Market, By Product Type Segment: Revenue Growth Analysis
27 Biologics Market, By Region, 2020-2028 (USD Billion)
28 Biosimilars Market, By Region, 2020-2028 (USD Billion)
29 Global Non-oncology Biologics and Biosimilarslars Market: By Application Type Scope Key Takeaways
30 Global Non-oncology Biologics and Biosimilarslars Market, By Application Type Segment: Revenue Growth Analysis
31 Cardiology Market, By Region, 2020-2028 (USD Billion)
32 Dermatology Market, By Region, 2020-2028 (USD Billion)
33 Hematology Market, By Region, 2020-2028 (USD Billion)
34 Endocrinology Market, By Region, 2020-2028 (USD Billion)
35 Neurology Market, By Region, 2020-2028 (USD Billion)
36 Immunology Market, By Region, 2020-2028 (USD Billion)
37 Respiratory Market, By Region, 2020-2028 (USD Billion)
38 Rheumatology Market, By Region, 2020-2028 (USD Billion)
39 Ophthalmology Market, By Region, 2020-2028 (USD Billion)
40 Other Applications Market, By Region, 2020-2028 (USD Billion)
41 Regional Segment: Revenue Growth Analysis
42 Global Non-oncology Biologics and Biosimilarslars Market: Regional Analysis
43 North America Non-oncology Biologics and Biosimilarslars Market Overview
44 North America Non-oncology Biologics and Biosimilarslars Market, By Drug Category
45 North America Non-oncology Biologics and Biosimilarslars Market, By Product Type
46 North America Non-oncology Biologics and Biosimilarslars Market, By Application Type
47 North America Non-oncology Biologics and Biosimilarslars Market, By Country
48 U.S. Non-oncology Biologics and Biosimilarslars Market, By Drug Category
49 U.S. Non-oncology Biologics and Biosimilarslars Market, By Product Type
50 U.S. Non-oncology Biologics and Biosimilarslars Market, By Application Type
51 Canada Non-oncology Biologics and Biosimilarslars Market, By Drug Category
52 Canada Non-oncology Biologics and Biosimilarslars Market, By Product Type
53 Canada Non-oncology Biologics and Biosimilarslars Market, By Application Type
54 Mexico Non-oncology Biologics and Biosimilarslars Market, By Drug Category
55 Mexico Non-oncology Biologics and Biosimilarslars Market, By Product Type
56 Mexico Non-oncology Biologics and Biosimilarslars Market, By Application Type
57 Four Quadrant Positioning Matrix
58 Company Market Share Analysis
59 AbbVie Inc.: Company Snapshot
60 AbbVie Inc.: SWOT Analysis
61 AbbVie Inc.: Geographic Presence
62 Sanofi: Company Snapshot
63 Sanofi: SWOT Analysis
64 Sanofi: Geographic Presence
65 Amgen Inc.: Company Snapshot
66 Amgen Inc.: SWOT Analysis
67 Amgen Inc.: Geographic Presence
68 Bristol-Myers Squibb Company: Company Snapshot
69 Bristol-Myers Squibb Company: Swot Analysis
70 Bristol-Myers Squibb Company: Geographic Presence
71 Eli Lilly and Company: Company Snapshot
72 Eli Lilly and Company: SWOT Analysis
73 Eli Lilly and Company: Geographic Presence
74 F. Hoffmann-La Roche Ltd.: Company Snapshot
75 F. Hoffmann-La Roche Ltd.: SWOT Analysis
76 F. Hoffmann-La Roche Ltd.: Geographic Presence
77 Johnson & Johnson : Company Snapshot
78 Johnson & Johnson : SWOT Analysis
79 Johnson & Johnson : Geographic Presence
80 Novartis AG: Company Snapshot
81 Novartis AG: SWOT Analysis
82 Novartis AG: Geographic Presence
83 Pfizer Inc., Inc.: Company Snapshot
84 Pfizer Inc., Inc.: SWOT Analysis
85 Pfizer Inc., Inc.: Geographic Presence
86 Other Companies: Company Snapshot
87 Other Companies: SWOT Analysis
88 Other Companies: Geographic Presence
The Global Non-oncology Biologics and Biosimilars Market has been studied from the year 2019 till 2028. However, the CAGR provided in the report is from the year 2023 to 2028. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Non-oncology Biologics and Biosimilars Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
Frequently Asked Questions
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Or view our licence options:
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS
